Newsletter

Exelixis Receives FDA Approval for Cabometyx to Treat Renal Cell Carcinoma

On December 19, Exelixis, Inc. (EXEL) announced that the company received additional FDA approval for its drug, Cabometyx. The drug received a label expansion so that it can be used to treat previously untreated advanced renal cell carcinoma. Cabometyx already experienced strong sales in the first nine months of 2017 due to strong demand for […]

0Comments

November 2017 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November 2017 Scorecard Number of Signals 21 Percent Correct – Next Close to 5-day Peak 85.7% Avg Increase – Next Close to 5-day Peak 9.3% Other stats: Number of signals over $10/share 13 […]

0Comments

Catalyst Pharmaceuticals Announces Positive Phase 3 Clinical Trial Results

On November 27, Catalyst Pharmaceutical, Inc. (CPRX) announced positive phase 3 clinical trial results from its drug Firdapse. This was the second phase 3 trial of Firdapse, which shows statistically significant improvement for symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). LEMS is a rare autoimmune disorder in which nerves have trouble sending to muscle cells, […]

0Comments

Lannett Announces FDA Acceptance of New Drug Application

On December 1, Lannett Company, Inc. (LCI) announced FDA acceptance of its 505(b)(2) New Drug Application (NDA) for Cocaine Hydrochloride (HCl) Topical Solution. The drug is a proprietary local topical anesthetic with the proposed name Numbrino. The submission is supported by two successful Phase 3 clinical trials.   Rocket Tickers detected the event and sent […]

0Comments

Emergent Biosolutions Receives FDA Approval for Vaccine Production

On November 20, Emergent Biosolutions Inc. (EBS) announced that the company received FDA approval on its supplemental Biologics License Application (sBLA) for the production of the ACAM2000 vaccine. This live vaccine for smallpox will be manufactured in the company’s new live viral manufacturing facility in Canton, Massachusetts. It is the only vaccine approved by the […]

0Comments

Collegium Receives FDA Approval for Xtampza® ER

On November 7, Collegium Pharamceutical, Inc. (COLL) announced FDA approval of its supplemental new drug application for Xtampza® ER. The drug is an abuse-deterrent, extended-release opiod, for severe pain management needing daily, long-term relief. This is an important advance considering the opiod addiction epidemic in the United States. Xtampza® ER is the only single-agent oxycodone with the […]

0Comments

Promising Clinical Trial Results From Flex Pharma

On November 6, Flex Pharma Inc. (FLKS) reported positive stage 2 clinical trial results for a new drug to treat cramps and spasticity associated with a variety of neurological disorders. Positive topline data for FLX-787 indicates that significant improvement of pain and cramping is possible for those suffering from multiple sclerosis (MS), amyotrophic lateral sclerosis […]

0Comments

October 2017 Scorecard

The scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October 2017 Scorecard Number of Signals 22 Percent Correct – Next Open to 5-day Peak 95.5% Avg Increase – Next Open to 5-day Peak 7.8% Other stats: Number of signals over $10/share 15 Number of […]

0Comments

AbbVie Reports Promising Phase 3 Clinical Trial Results

AbbVie (ABBV), in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced detailed results from two phase 3 clinical trial extension studies on November 1. The studies were analyzing the long-term efficacy and safety of Elagolix, a drug for the managing the pain associated with endometriosis. The results showed no increased safety concern after twelve months along […]

0Comments

September 2017 Scorecard

The scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: September 2017 Scorecard Number of Signals 34 Percent Correct – Next Open to 5-day Peak 100% Avg Increase – Next Open to 5-day Peak 11.4% Other stats: Number of signals over $10/share 21 Number of […]

0Comments